Document Detail

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
MedLine Citation:
PMID:  11346336     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif). DESIGN: The effects of 2 randomized doses of 6.5 mg/m(2) per day (with crossover for progression) vs 650 mg/m(2) per day (later modified to 300 mg/m(2) per day) were evaluated in an open-label, multicenter, phase 2 and 3 study conducted between February 1997 and November 1998. SETTING: Eighteen international cutaneous T-cell lymphoma clinics at academic referral centers. PATIENTS: Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were intolerant of) treatment or had reached at least a 6-month response plateau under at least 2 forms of prior therapy (median of 3.5 prior therapies). INTERVENTION: Bexarotene (Targretin capsules) administered once daily with meal for 16 weeks or longer. MAIN OUTCOME MEASURES: Primary end point classification of overall response rate of complete and partial remissions determined by either the Physician's Global Assessment of Clinical Condition or the objective Composite Assessment of Index Lesion Severity. Body surface area, time to response, duration of disease control, time to disease progression, individual index lesion signs and symptoms, and quality of life parameters were secondary outcomes. RESULTS: Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%). The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively. Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded. The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days. The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]). No cases of drug-related neutropenic fever, sepsis, or death occurred. Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day. CONCLUSIONS: Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day. Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
M Duvic; A G Martin; Y Kim; E Olsen; G S Wood; C A Crowley; R C Yocum;
Related Documents :
16966366 - Phase i study of aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with...
19825886 - Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependen...
12114416 - A phase i and pharmacokinetic study of sam486a, a novel polyamine biosynthesis inhibito...
20444846 - Combining gemcitabine, oxaliplatin and capecitabine (gemoxel) for patients with advance...
11447376 - Alternative agents in asthma.
2932416 - Bactericidal activity of ciprofloxacin in serum and urine against escherichia coli, pse...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Archives of dermatology     Volume:  137     ISSN:  0003-987X     ISO Abbreviation:  Arch Dermatol     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-05-10     Completed Date:  2001-06-07     Revised Date:  2008-03-17    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  581-93     Citation Subset:  AIM; IM    
M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anticarcinogenic Agents / administration & dosage*,  adverse effects,  pharmacokinetics,  therapeutic use
Cross-Over Studies
Dose-Response Relationship, Drug
Lymphoma, T-Cell / drug therapy*,  pathology,  physiopathology
Middle Aged
Neoplasm Staging
Quality of Life
Skin Neoplasms / drug therapy*,  pathology,  physiopathology
Survival Analysis
Tetrahydronaphthalenes / administration & dosage*,  adverse effects,  pharmacokinetics,  therapeutic use
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Capsules; 0/Tetrahydronaphthalenes; 0/bexarotene
Comment In:
Arch Dermatol. 2001 May;137(5):649-52   [PMID:  11346343 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Infantile hemangiomas: speculation on placental trophoblastic origin.
Next Document:  Factor V Leiden mutation in postthrombotic and non-postthrombotic venous ulcers.